Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | MPO | P05164 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
| ▸ | TACR1 | P25103 | 2/20 | 0.62 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | HTR1D | P28221 | 1/20 | 0.55 |
| ▸ | HTR1B | P28222 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | HTR1E | P28566 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL475351 | 0.93 | MAPT (0.74) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL289044 | 0.93 | MAPT (0.74) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL21059260 | 0.90 | MAPT (0.70) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL17503190 | 0.89 | MAPT (0.72) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL28780405 | 0.89 | MAPT (0.72) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL626831 | 0.89 | MAPT (0.72) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL23723484 | 0.89 | MAPT (0.76) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL29472033 | 0.89 | MAPT (0.76) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL9728383 | 0.88 | MAPT (0.64) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL220264 | 0.88 | MAPT (0.67) | MAPTKDM4EMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115772513-A | D-carbamyl hydrolase mutant, gene, expression vector and application thereof | 江南大学 | 2023-03-10 | — | — | CN | disclosed |
| US-20120184532-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC (US) | 2012-07-19 | — | — | US | disclosed |
| US-20110190267-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110098278-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC (US) | 2011-04-28 | — | — | US | disclosed |
| US-7217523-B2 | Nucleoside phosphoramidates and nucleoside phosphoramidases | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1575900-A4 | N-METHYL AMINO ACIDS | UBIQUITOUS TECHNOLOGIES PTY LT (AU) | 2007-02-21 | — | — | EP | disclosed |
| US-7163671-B2 | Long-term stabilized formulations | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20060014193-A1 | Nucleoside phosphoramidates and nucleoside phosphoramidases | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2006-01-19 | — | — | US | disclosed |
| US-20050245432-A1 | N-methyl amino acids | UBIQUITOUS TECHNOLOGIES PTY. LTD. (AU) | 2005-11-03 | — | — | US | disclosed |
| EP-1575900-A1 | N-METHYL AMINO ACIDS | UBIQUITOUS TECHNOLOGIES PTY LTD (AU) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004007427-A1 | N-METHYL AMINO ACIDS | UBIQUITOUS TECHNOLOGIES PTY LTD (AU) | 2004-01-22 | — | — | WO | disclosed |
| US-20030092622-A1 | Preparation stabilized over long time | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-05-15 | — | — | US | disclosed |
| EP-1260230-A1 | PREPARATIONS STABILIZED OVER LONG TIME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245432-A1 | N-methyl amino acids | VIP, NPPA, PTMS | MAPT 2745/4885KDM4E 972/4885MEN1 477/4885 |
| US-20110098278-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | PEPD, VIP, GALR1 | MAPT 365/4885KDM4E 2154/4885MEN1 3359/4885 |
| US-20110190267-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | OPRK1, OPRL1, OPRM1 | MAPT 2248/4885KDM4E 1479/4885MEN1 4826/4885 |
| US-20120184532-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | PEPD, VIP, GALR1 | MAPT 365/4885KDM4E 2154/4885MEN1 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.